Clinical Trial Update: Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating alanyl-glutamine supplementation for the treatment of Clostridioides difficile infection is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Colitis
• Clostridioides Difficile Infection

Drugs mentioned

• Alanyl-glutamine (alanyl-glutamine)

Snippet

Sponsor: University of Virginia | Conditions: Clostridioides Difficile Infection, Clostridium Difficile Infection | Phase 2 | Status: RECRUITING